相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer
Nadina Tinsley et al.
ONCOLOGIST (2020)
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
Wungki Park et al.
BRITISH JOURNAL OF CANCER (2020)
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S. Trebeschi et al.
ANNALS OF ONCOLOGY (2019)
Neutrophil-lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB)
Fangping Ren et al.
ONCOTARGETS AND THERAPY (2019)
Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications
Biagio Ricciuti et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Lorenza Landi et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers
Maria Panagopoulou et al.
ONCOGENE (2019)
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
Arsela Prelaj et al.
CANCERS (2019)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer
Kathryn C. Arbour et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
Mina Georgieva et al.
LUNG CANCER (2018)
Recovery of gut microbiota of healthy adults following antibiotic exposure
Albert Palleja et al.
NATURE MICROBIOLOGY (2018)
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors
Vivek Verma et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
MatureP: prediction of secreted proteins with exclusive information from their mature regions
Georgia Orfanoudaki et al.
SCIENTIFIC REPORTS (2017)
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
Ashley M. Hopkins et al.
BRITISH JOURNAL OF CANCER (2017)
Proton pump inhibitors affect the gut microbiome
Floris Imhann et al.
GUT (2016)
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Benjamin Weide et al.
CLINICAL CANCER RESEARCH (2016)
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss
Lisa Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Marie Vetizou et al.
SCIENCE (2015)
Albumin and Neutrophil Combined Prognostic Grade as a New Prognostic Factor in Non-Small Cell Lung Cancer: Results from a Large Consecutive Cohort
Haifeng Sun et al.
PLOS ONE (2015)
Role of the Microbiota in Immunity and Inflammation
Yasmine Belkaid et al.
CELL (2014)
Prognostic Factors in Patients with Advanced Cancer: A Comparison of Clinicopathological Factors and the Development of an Inflammation-Based Prognostic System
Barry J. Laird et al.
CLINICAL CANCER RESEARCH (2013)
Definition and classification of cancer cachexia: an international consensus
Kenneth Fearon et al.
LANCET ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
